BIO
NYSE · Life Sciences Tools & Services
Bio-Rad Laboratories-A
$376.41
-6.00 (-1.57%)
Financial Highlights (FY 2026)
Revenue
2.58B
Net Income
759.97M
Gross Margin
52.0%
Profit Margin
29.4%
Rev Growth
-2.7%
D/E Ratio
0.16
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 52.0% | 52.0% | 34.0% | 34.0% |
| Operating Margin | 1.6% | 1.4% | 7.9% | 9.4% |
| Profit Margin | 29.4% | 28.0% | 8.4% | 9.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.58B | 2.65B | 3.74B | 3.63B |
| Gross Profit | 1.34B | 1.38B | 1.27B | 1.24B |
| Operating Income | 41.08M | 37.99M | 295.48M | 340.82M |
| Net Income | 759.97M | 702.81M | 316.01M | 332.31M |
| Gross Margin | 52.0% | 52.0% | 34.0% | 34.0% |
| Operating Margin | 1.6% | 1.4% | 7.9% | 9.4% |
| Profit Margin | 29.4% | 28.0% | 8.4% | 9.2% |
| Rev Growth | -2.7% | -2.7% | +9.0% | +2.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 713.60M | 713.60M | 3.59B | 2.84B |
| Total Equity | 4.42B | 4.42B | 4.06B | 4.19B |
| D/E Ratio | 0.16 | 0.16 | 0.89 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 41.20M | 40.22M | 492.25M | 510.81M |
| Free Cash Flow | — | — | 138.31M | 190.89M |